Holen Sie sich die Stockscreener-App
20.70
1.05%
-0.235
Schlusskurs vom Vortag:
$20.93
Offen:
$20.82
24-Stunden-Volumen:
922.74K
Relative Volume:
0.60
Marktkapitalisierung:
$3.23B
Einnahmen:
$340.81M
Nettoeinkommen (Verlust:
$-419.65M
KGV:
-7.2614
EPS:
-2.85
Netto-Cashflow:
$-402.10M
1W Leistung:
+15.12%
1M Leistung:
+23.20%
6M Leistung:
+43.12%
1J Leistung:
-11.04%
1-Tages-Spanne:
$20.61
$21.39
1-Wochen-Bereich:
$17.18
$21.39
52-Wochen-Spanne:
$10.57
$24.34
Denali Therapeutics Inc Stock (DNLI) Company Profile
Firmenname
Denali Therapeutics Inc
Sektor
Branche
Telefon
(650) 866-8547
Adresse
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Vergleichen Sie DNLI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
20.71 | 3.27B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.95 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.78 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.78 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-04-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2025-01-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-01-03 | Eingeleitet | William Blair | Outperform |
| 2024-12-16 | Hochstufung | Stifel | Hold → Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-10-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-09-06 | Eingeleitet | B. Riley Securities | Buy |
| 2023-01-30 | Eingeleitet | SVB Securities | Outperform |
| 2022-12-05 | Eingeleitet | Cowen | Outperform |
| 2022-11-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-11-02 | Eingeleitet | BofA Securities | Buy |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-09-21 | Eingeleitet | Oppenheimer | Outperform |
| 2021-09-01 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-05-18 | Eingeleitet | UBS | Buy |
| 2021-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-13 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-02-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-02-24 | Eingeleitet | Jefferies | Buy |
| 2020-02-19 | Eingeleitet | Stifel | Hold |
| 2020-01-27 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-26 | Eingeleitet | Wedbush | Neutral |
| 2019-09-13 | Eingeleitet | Nomura | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-06-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-11-12 | Eingeleitet | Janney | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-01-02 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Eingeleitet | Goldman | Neutral |
| 2018-01-02 | Eingeleitet | JP Morgan | Overweight |
| 2018-01-02 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Denali Therapeutics Inc Aktie (DNLI) Neueste Nachrichten
Denali Therapeutics (NASDAQ:DNLI) Shares Up 11.3%Here's Why - MarketBeat
Shorts Report: What are analysts price targets for Denali Therapeutics IncExit Point & AI Forecast for Swing Trade Picks - baoquankhu1.vn
3 Biotech Stocks That Could Double In 2026 - AOL.com
Stock Market Recap: What are analysts price targets for Denali Therapeutics IncJuly 2025 Rallies & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Liquidity Mapping Around (DNLI) Price Events - Stock Traders Daily
Aug Big Picture: Can Denali Therapeutics Inc withstand a market correctionRate Hike & Daily Volume Surge Signals - baoquankhu1.vn
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Buy" by Brokerages - MarketBeat
Aug Breakouts: Whats the outlook for Denali Therapeutics Incs sectorPrice Action & Community Trade Idea Sharing Platform - baoquankhu1.vn
Aug Chart Watch: Whats the outlook for Denali Therapeutics Incs sectorAnalyst Downgrade & Long Hold Capital Preservation Plans - baoquankhu1.vn
An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 40% Undervalued - 富途资讯
Campbell & CO Investment Adviser LLC Purchases 74,066 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Aug Patterns: Can Denali Therapeutics Inc withstand a market correctionMarket Performance Recap & Weekly High Conviction Trade Ideas - baoquankhu1.vn
FOMO Trade: What makes FTRE stock attractive todayInflation Watch & Smart Allocation Stock Reports - baoquankhu1.vn
Denali Therapeutics stock maintains Buy rating at Goldman Sachs on pipeline progress - Investing.com
Earnings Recap: Is BranchOut Food Inc a strong growth stockAnalyst Upgrade & AI Powered Market Trend Analysis - baoquankhu1.vn
Bear Alert: Will Denali Therapeutics Inc benefit from government policy2025 Market Overview & Fast Entry High Yield Stock Tips - baoquankhu1.vn
DNLI: Imminent approval and strong clinical progress drive growth for transferrin receptor-enabled therapies - TradingView — Track All Markets
Denali Therapeutics unveils portfolio goals for 2026, stock up - MSN
Market Outlook: Is Denali Therapeutics Inc a turnaround storyStop Loss & Stock Portfolio Risk Management - baoquankhu1.vn
Denali Therapeutics Inc. (DNLI) Stock Analysis: Exploring An 83% Upside Potential - DirectorsTalk Interviews
Rate Hike: Can Denali Therapeutics Inc scale operations efficientlyQuarterly Investment Review & Stepwise Trade Signal Implementation - baoquankhu1.vn
Have Denali Therapeutics Insiders Been Selling Stock? - simplywall.st
Why (DNLI) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Is Denali Therapeutics Inc. stock a good choice for value investors2025 Technical Patterns & Daily Volume Surge Trade Alerts - ulpravda.ru
What insider trading reveals about Denali Therapeutics Inc. stockRecession Risk & AI Powered Market Trend Analysis - Улправда
Investment Recap: Is Denali Therapeutics Inc stock recession proof2025 Top Gainers & Precise Buy Zone Identification - moha.gov.vn
DNLI Stock Price, Forecast & Analysis | DENALI THERAPEUTICS INC (NASDAQ:DNLI) - Chartmill
Why analysts upgrade Denali Therapeutics Inc. stockQuarterly Trade Report & Low Drawdown Momentum Trade Ideas - Улправда
What RSI levels show for Denali Therapeutics Inc. (4DN) stockJuly 2025 Drop Watch & Low Risk Growth Stock Ideas - Улправда
What dividend safety score for Denali Therapeutics Inc. stockJuly 2025 Weekly Recap & Long-Term Safe Return Strategies - Улправда
Ryan Watts Sells 35,198 Shares of Denali Therapeutics (NASDAQ:DNLI) Stock - MarketBeat
Denali Therapeutics CEO Ryan J. Watts Sells Shares - TradingView — Track All Markets
Is Denali Therapeutics Inc. stock recession proofJuly 2025 Final Week & AI Powered Buy and Sell Recommendations - Улправда
Will Denali Therapeutics Inc. stock reach all time highs in 2025Quarterly Market Summary & Long-Term Growth Plans - Улправда
What risks investors should watch in Denali Therapeutics Inc. stockStochastic Oscillator Alerts & Outstanding Profit Investment - Улправда
Assessing Denali Therapeutics (DNLI) Valuation After Positive Hunter Syndrome Trial Data And FDA Priority Review - Yahoo Finance
The Bull Case For Denali Therapeutics (DNLI) Could Change Following NEJM Tividenofusp Data Publication And FDA Review - Yahoo Finance
Performance Recap: Will Denali Therapeutics Inc. stock reach all time highs in 20252025 EndofYear Setup & Risk Managed Investment Entry Signals - Bộ Nội Vụ
Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up - sharewise.com
Will Denali Therapeutics Inc. stock see insider buyingMarket Depth Overview & Unlock Patterns Humans Can’t See - Улправда
Denali Therapeutics outlines key milestones for 2026 By Investing.com - Investing.com Nigeria
Denali Therapeutics stock rating initiated at Buy by UBS on Hunter syndrome drug potential - Investing.com South Africa
Can Denali Therapeutics Inc. (4DN) stock sustain institutional flows2026 world cup usa national team round of 32 young talents transition play winner prediction expert opinion - ulpravda.ru
Denali Prepares For Key Clinical And Regulatory Milestones - Nasdaq
Denali Therapeutics announces key anticipated milestones and priorities for 2026 - MarketScreener
Denali Therapeutics outlines key milestones for 2026 - Investing.com
Denali Therapeutics Sets 2026 Priorities Ahead of Tividenofusp Decision - TipRanks
Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome - The Manila Times
Denali Therapeutics Inc Announces Key Milestones and Priorities for 2026 - TradingView — Track All Markets
Hunter syndrome drug nears FDA decision as new brain therapies move ahead - Stock Titan
Denali Therapeutics announces $200M proposed offering of common stock and pre-funded warrants - MSN
Finanzdaten der Denali Therapeutics Inc-Aktie (DNLI)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.38%
1.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):